The guidance help provide primary care prescribers the tools to help identify and manage patients of childbearing age on valproate. While the MHRA have advise on the desired outcome the guidance we published was aimed at giving practical advice and using the clinical systems to provide as much support for practices in helping them achieve this.
We are expecting this to reduce the unnecessary prescribing of valproate and ensure that patients who continue valproate are doing so in a safe and effective manner with the correct oversight from a specialist.
